Work Here?
Overview
GATC Health uses artificial intelligence to speed up drug discovery and disease prediction. Its MAT platform analyzes genomics, proteomics, and metabolomics with AI and neural networks to identify drug targets, design candidates, and predict safety and efficacy before lab testing, processing 400 trillion data points in under eight minutes with UC Irvine validation. It both develops its own drug candidates and partners with pharma and biotech firms to accelerate development, de-risk pipelines, and reassess failed assets, including a partnership with MCI to forecast trial endpoints for underwriting clinical trials. Its goal is to shorten the time and cost to bring drugs to market and to change how clinical trial financing works by providing predictive insights that reduce risk.
About GATC Health
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Seed
Total Funding
$2.3M
Headquarters
Irvine, California
Founded
2020
Get referred to GATC Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- GATC signed a February 23, 2026 MSA with a public neuropsychiatric biopharma company.
- GATC expanded leadership with Mark Flather and Fred Brown on February 26, 2026.
- June 2026 Sanofi, DIA, and media appearances show rising commercial visibility.
What critics are saying
- 2024 revenue was $62,500 against a $103.4 million net loss, signaling burn.
- The BioAtla $40 million SPV closes $35 million only if Inversagen funds in Q1 2026.
- GATC Health has no disclosed product revenue scale; one bad model ruins credibility quickly.
What makes GATC Health unique
- GATC Health's MAT platform simulates human biology, pairing multiomics with AI risk prediction.
- Its Derisq and Operon tools sell into drug developers, investors, and regulators.
- The MCI-Lloyd's insurance program ties GATC models directly to financing clinical-trial risk.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$2.3M
Below
Industry Average
Funded Over
3 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↓ -3%GATC Health has appointed Mark Flather as senior vice president of business development and strategy, and Fred Brown as senior adviser for pharma partnerships and strategy. The appointments aim to accelerate adoption of the company's Derisq AI risk prediction tool and Operon AI platform amongst biotech investors and pharmaceutical partners. Flather brings over 30 years of capital markets experience, including 13 years in drug discovery and biopharma. He previously spent eight years with equity hedge fund Hermes Advisors. Brown contributes decades of experience in advancing and commercialising therapeutic portfolios. The California-based tech-bio company is expanding engagement with public biopharma companies, institutional investors and pharmaceutical partners. Chief operations officer Gene O'Bryan said the appointments strengthen GATC's ability to bridge AI innovation with market adoption.
BioAtla and GATC Health announce a $40 million special purpose vehicle (SPV) Transaction to advance ozuriftamab vedotin (Oz-V) into a registrational trial for 2L+ oropharyngeal squamous cell carcinoma (OPSCC). Rhea-AI summary. BioAtla (Nasdaq: BCAB) and GATC Health announced a $40 million SPV financing to advance ozuriftamab vedotin (Oz-V) into a registrational Phase 3 trial for 2L+ oropharyngeal squamous cell carcinoma (OPSCC). BioAtla will receive an initial $5 million at closing and expects the remaining $35 million in Q1 2026; BioAtla will retain 65% ownership of Oz-V while Inversagen AI will hold 35%. BioAtla will lead Phase 3 execution with enrollment anticipated to begin in early 2026 and a data path toward potential accelerated approval in the US. * $5M initial cash to fund operations and Phase 3 OPSCC costs * Remaining $35M committed pending Q1 2026 close * BioAtla retains 65% ownership of Oz-V across solid tumors * Phase 3 enrollment expected early 2026 targeting registrational path * Closing of remaining $35M is conditional on Inversagen AI financings * Transaction grants Inversagen AI a 35% stake, diluting BioAtla economic interest
IRVINE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) - GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, today announced the launch of a strategic program with The University of Alabama (UA) designed to transform how academic discoveries advance into market-ready therapies.
Dr. Gupta, Director, White House Office of National Drug Control Policy (2021-2025), to lead AI-powered drug discovery group.IRVINE, Calif., May 1, 2025 /PRNewswire/ -- GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, is proud to announce that Dr. Rahul Gupta, MD, MPH, MBA, has joined the company as its new president. GATC Health, a trailblazer in tech-bio innovation, is leveraging cutting-edge artificial intelligence (AI) to revolutionize the field of drug discovery. Dr. Gupta's exceptional career in public health leadership, medical innovation, and policy development brings unparalleled expertise to guide GATC Health as it embarks on its next phase of strategic growth
Former U.S. Drug czar Dr. Rahul Gupta joins GATC Health as president.
GATC Health is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About GATC Health
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Seed
Total Funding
$2.3M
Headquarters
Irvine, California
Founded
2020
GATC Health is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today